Abstract: The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

Abstract: The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino} butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

Abstract: The present invention relates to a protective packaging for a container accommodating a light-sensitive substance, the packaging comprising: an opaque cover to completely enclose the container for transportation and/or storage in a sealed storage configuration, wherein the cover is transferable from said storage configuration into an application configuration by means of an opening structure which is adapted to provide access to at least one port structure of the container from outside the cover.

Abstract: The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

Abstract: The invention relates to a pharmaceutical composition comprising methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.

Abstract: The invention concerns a method for the preparation of additives for influencing the electrocrystalline growth in aprotic oxygen- and water-free organo-aluminum electrolyte media. A compound which contains a sulfonimide or sulfonamide group as the reactable group, preferably, N-benzoylbenzenesulfonimide, optionally in the presence of an inert organic solvent, is reacted with at least one organoaluminum compound of the general formula AlR.sub.3, where R is an alkyl radical, in the ratio of 1:1 to 1:6.The additives obtained furnish a bright aluminum coating on metals and conductive materials in direct electrodeposition.